Alessia Mercalli

Alessia Mercalli

Auto-generated profile, based on publicly available information

Alessia Mercalli

Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2020 in Diabetologia
Verified
Journal Article
Closed access
PDF file
VLVito Lampasona
Vito Lampasona
SMSecchi Massimiliano
Secchi Massimiliano
MSMarina Scavini
Marina Scavini
EBElena Bazzigaluppi
Elena Bazzigaluppi
CBCristina Brigatti
Cristina Brigatti
LPLorenzo Piemonti
Lorenzo Piemonti

30 September 2022 in Annals of Surgery
Verified
Journal Article
Open access
Gianpaolo BalzanoGianpaolo Balzano
Gianpaolo Balzano
AZAlessandro Zerbi
Alessandro Zerbi
FAFrancesca Aleotti
Francesca Aleotti
GCGiovanni Capretti
Giovanni Capretti
RMRaffella Bsc Melzi
Raffella Bsc Melzi
LPLorenzo Piemonti
Lorenzo Piemonti
Objective: To compare pancreaticoduodenectomy (PD) and total pancreatectomy (TP) with islet autotransplantation (IAT) in patients at high risk of postoperative pancreatic fistula (POPF). Background: Criteria to predict the risk of POPF occurrence after PD are available. However, even when a high risk of POPF is predicted, TP is not currently accepted as an alternative to PD, because of its severe consequences on glycaemic control. Combining IAT with TP may mitigate such consequences. Methods: Randomized, open-label, controlled, bicentric trial (NCT01346098). Candidates for PD at high-risk pancreatic anastomosis (ie, soft pancreas and duct diameter ≤3 mm) were randomly assigned (1:1) to undergo either PD or TP-IAT. The primary endpoint was the incidence of complications within 90 days after surgery. Results: Between 2010 and 2019, 61 patients were assigned to PD (n=31) or TP-IAT (n=30). In the intention-to-treat analysis, morbidity rate was 90·3% after PD and 60% after TP-IAT (P=0.008). According to complications’ severity, PD was associated with an increased risk of grade ≥2 [odds ratio (OR)=7.64 (95% CI: 1.35–43.3), P=0.022], while the OR for grade ≥3 complications was 2.82 (95% CI: 0.86–9.24, P=0.086). After TP-IAT, the postoperative stay was shorter [median: 10.5 vs 16.0 days; P<0.001). No differences were observed in disease-free survival, site of recurrence, disease-specific survival, and overall survival. TP-IAT was associated with a higher risk of diabetes [hazard ratio=9.1 (95% CI: 3.76–21.9), P<0.0001], but most patients maintained good metabolic control and showed sustained C-peptide production over time. Conclusions: TP-IAT may become the standard treatment in candidates for PD, when a high risk of POPF is predicted.

29 October 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ALAndrea Laurenzi
Andrea Laurenzi
ACAmelia Caretto
Amelia Caretto
CMChiara Molinari
Chiara Molinari
AMAlessia Mercalli
Alessia Mercalli
RMRaffaella Melzi
Raffaella Melzi
LPLorenzo Piemonti
Lorenzo Piemonti
Purpose: To assess whether dysglycemia diagnosed during severe acute respiratory syndrome coronavirus 2 pneumonia may become a potential public health problem after resolution of the infection. In an adult cohort with suspected coronavirus disease 2019 (COVID-19) pneumonia, we integrated glucose data upon hospital admission with fasting blood glucose (FBG) in the year prior to COVID-19 and during postdischarge follow-up. Methods: From February 25 to May 15, 2020, 660 adults with suspected COVID-19 pneumonia were admitted to the San Raffaele Hospital (Milan, Italy). Through structured interviews/ medical record reviews, we collected demographics, clinical features, and laboratory tests upon admission and additional data during hospitalization or after discharge and in the previous year. Upon admission, we classified participants according to American Diabetes Association criteria as having (1) preexisting diabetes, (2) newly diagnosed diabetes, (3) hyperglycemia not in the diabetes range, or (4) normoglycemia. FBG prior to admission and during follow-up were classified as normal or impaired fasting glucose and fasting glucose in the diabetes range. Results: In patients with confirmed COVID (n = 589), the proportion with preexisting or newly diagnosed diabetes, hyperglycemia not in the diabetes range and normoglycemia was 19.6%, 6.7%, 43.7%, and 30.0%, respectively. Patients with dysglycemia associated to COVID-19 had increased markers of inflammation and organs’ injury and poorer clinical outcome compared to those with normoglycemia. After the infection resolved, the prevalence of dysglycemia reverted to preadmission frequency. Conclusions: COVID-19–associated dysglycemia is unlikely to become a lasting public health problem. Alarmist claims on the diabetes risk after COVID-19 pneumonia should be interpreted with caution.

5 August 2021 in Biology
Verified
Journal Article
Open access
PDF file
ALAndrea Laurenzi
Andrea Laurenzi
ACAmelia Caretto
Amelia Caretto
CMChiara Molinari
Chiara Molinari
EBElena Bazzigaluppi
Elena Bazzigaluppi
CBCristina Brigatti
Cristina Brigatti
LPLorenzo Piemonti
Lorenzo Piemonti
Aim. The aim of the current study was to compare clinical characteristics, laboratory findings, and major outcomes of patients hospitalized for COVID-19 pneumonia with COVID-associated hyperglycaemia or pre-existing diabetes. Methods. A cohort of 176 adult patients with a diagnosis of pre-existing diabetes (n = 112) or COVID-associated hyperglycaemia (n = 55) was studied. Results. Patients with COVID-associated hyperglycaemia had lower BMI, significantly less comorbidities, and higher levels of inflammatory markers and indicators of multi-organ injury than those with pre-existing diabetes. No differences between pre-existing diabetes and COVID-associated hyperglycaemia were evident for symptoms at admission, the humoral response against SARS-CoV-2, or autoantibodies to glutamic acid decarboxylase or interferon alpha-4. COVID-associated hyperglycaemia was independently associated with the risk of adverse clinical outcome, which was defined as ICU admission or death (HR 2.11, 95% CI 1.34–3.31; p = 0.001), even after adjustment for age, sex, and other selected variables associated with COVID-19 severity. Furthermore, at the same time, we documented a negative association (HR 0.661, 95% CI 0.43–1.02; p = 0.063) between COVID-associated hyperglycaemia to swab negativization. Conclusions. Recognizing hyperglycaemia as a specific clinical entity associated with COVID-19 pneumonia is relevant for early and appropriate patient management and close monitoring for the progression of disease severity.

23 April 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
FAFrancesca Aleotti
Francesca Aleotti
Gianpaolo BalzanoGianpaolo Balzano
Gianpaolo Balzano
RMRaffella Melzi
Raffella Melzi
AMAlessia Mercalli
Alessia Mercalli
GCGiovanni Capretti
Giovanni Capretti
LPLorenzo Piemonti
Lorenzo Piemonti
Islet auto transplantation (IAT) is a potential therapeutic option for patients undergoing pancreatectomy to preserve endocrine function, but its role in patients with intraductal papillary mucinous neoplasms (IPMN) remains controversial due to oncological concerns. This study evaluates the feasibility, safety, and metabolic outcomes of IAT in seven patients with focal IPMN who underwent pancreatectomy between 2008 and 2023, following the Milan protocol. Primary outcomes included the technical success of islet isolation and the absence of tumor dissemination. Secondary outcomes involved insulin independence and metabolic control post-transplantation. Islet isolation success was variable, with four patients meeting the criteria for transplantation. The average islet yield was 1,097 islet equivalents per kilogram of body weight (range: 219-1,833 IEQ/kg). No patients experienced complications related to islet infusion, and there was no evidence of tumor recurrence or metastasis during a mean follow-up of 7.9 years (range: 3.99-11.88 years). IAT recipients demonstrated preserved insulin secretion, while non-transplanted patients developed diabetes. These findings support the feasibility and safety of IAT in carefully selected patients with focal IPMN, providing promising metabolic outcomes. The results open the possibility to initiate larger cohort studies and explore the potential to expand the population of patients who could benefit from this approach.

22 April 2021 in medRxiv
Verified
Preprint
Open access
PDF file
ALAndrea Laurenzi
Andrea Laurenzi
ACAmelia Caretto
Amelia Caretto
CMChiara Molinari
Chiara Molinari
EBElena Bazzigaluppi
Elena Bazzigaluppi
CBCristina Brigatti
Cristina Brigatti
LPLorenzo Piemonti
Lorenzo Piemonti
Objective The aim of the current study was to compare clinical characteristics, laboratory findings and major outcomes of patients hospitalized for COVID 19 pneumonia with new-onset or preexisting diabetes. Design A cohort of 176 adult patients with a diagnosis of pre-existing (n=112) or new-onset diabetes (n=55) and confirmed COVID-19 pneumonia was studied. Clinical outcomes and laboratory findings were analysed according to the presence of preexisting or new-onset diabetes. The time to viral clearance and the persistence of hyperglycemia were assessed during the follow-up after hospital discharge. Results Patients with new-onset diabetes had lower BMI, significantly less comorbidities and higher levels of inflammatory markers and indicators of multi-organ injury than those with preexisting diabetes. No differences between preexisting and new onset diabetes were evident for symptoms at admission, humoral response against SARS-CoV-2 or autoantibodies to glutamic acid decarboxylase or interferon alpha-4. New-onset diabetes was independently associated with the risk of adverse clinical outcome defined as ICU admission or death (HR 2.11, 95% CI 1.34-3.31; p=0.001), even after adjustment for age, sex and other selected variables associated with COVID-19 severity. Furthermore, we documented a negative association (HR 0.661, 95% CI 0.43-1.02; p=0.063) between new-onset diabetes and the time to swab negativization. During follow-up we observed that in 30% of the patients with new-onset diabetes hyperglycemia reversed when the viral infection resolved. Conclusions The recognition of new-onset diabetes as a specific clinical entity associated with COVID-19 pneumonia is relevant for early and appropriate patient management and close monitoring for the progression of disease severity.